Lurasidone-induced Parkinsonism and Hyperprolactinemia

Suthar, Navratan; Aneja, Jitender

doi:10.4103/ijpsym.ijpsym_274_18

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Lurasidone-induced Parkinsonism, severe EPS, and rabbit syndrome had also been reported. [14][15][16] It was suggested that the high affinity of lurasidone for D2 receptors in the nigrostriatal tract, in combination with poor anticholinergic activity, could lead to drug-induced Parkinsonism. Even though earlier studies 4,5 reported fewer EPS with lurasidone, the meta-analysis by Leucht et al 17 identified that lurasidone was one among the five second-generation antipsychotics with significantly more EPS than placebo (OR = 2.46; 95% CI: 1.55-3.72).…”

Section: Discussionmentioning

confidence: 99%

Can Isolated Head Tremors Be an Extrapyramidal Symptom Associated with Lurasidone?—A Case Series

Suriya

Simiyon

Thilakan

et al. 2021

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Can Isolated Head Tremors Be an Extrapyramidal Symptom Associated with Lurasidone?—A Case Series

Suriya

Simiyon

Thilakan

et al. 2021

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

“…A DBRCT (n = 496) with placebo control, using a 20-week stabilization phase and subsequent 28 week treatment period in BPD showed similar rates of DIMD as other long-term studies [ 71 ]. Case reports have identified individuals with TD, drug-induced parkinsonism, rabbit syndrome, and laryngospasm with lurasidone-exposure [ 72 73 74 75 76 ].…”

Section: Incidence Of Dimd With Novel Antipsychoticsmentioning

confidence: 99%

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents

Kannarkat

Caroff

Morley

2022

Tremor and Other Hyperkinetic Movements

View full text Add to dashboard Cite

Background: The last decade has seen development of numerous novel antipsychotic drugs with unique mechanisms including long-acting formulations for clinical use. A comparative assessment of these new drugs with each other and previous antipsychotics have not been performed with regards to risk for drug-induced movement disorders (DIMD). Methods: Medline was searched from January 2010 to February 2022 for primary research articles and review articles in English using the search terms “extrapyramidal” and “tardive” with individual drug names of novel antipsychotics. Results: We identified articles describing the risk of DIMD with 6 novel antipsychotics, 4 novel formulations, and 3 experimental antipsychotics. Both short- and long-term data generally showed comparable to lower risk of DIMD with novel antipsychotics and recent long-acting formulations compared to previously marketed antipsychotics. Discussion: Several novel antipsychotics, particularly lumateperone and pimavanserin, show promise in being able to treat psychosis while reducing the risk of DIMD. Long-acting paliperidone may reduce risk of DIMD while other long-acting injectable formulations of SGA have similar risk of DIMD compared to oral formulations. New drug targets for treating psychosis without dopamine blockade also show promise.

show abstract